LIFE aTyr Pharma Inc.

5.71
-0.19  -3%
Previous Close 5.9
Open 5.54
Price To Book 0.83
Market Cap 22,212,956
Shares 3,890,185
Volume 120,584
Short Ratio
Av. Daily Volume 294,879
Stock charts supplied by TradingView

NewsSee all news

  1. aTyr Pharma Announces Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of ATYR1923 in Japan

    aTyr eligible to receive up to $175 million in total payments, including $8 million upfront, plus tiered sales royalties Kyorin to fund all ATYR1923 development and commercialization activities in Japan SAN DIEGO, Jan.

  2. aTyr Pharma Announces Third Quarter 2019 Results and Provides Corporate Update

    Interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients due in December 2019 Company to host conference call and webcast today, November 14, at 5:00pm EDT SAN DIEGO,

  3. aTyr Pharma to Present at the Stifel Healthcare Conference 2019

    SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  4. aTyr Pharma to Announce Third Quarter Results on November 14th

    SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  5. aTyr Pharma Announces Research Collaboration with Boston Children's Hospital

    SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 final data presented October 5, 2017 at the International Annual Congress of the World Muscle Society (WMS).
Resolaris
Early onset facioscapulohumeral muscular dystrophy (FSHD)
Phase 1b/2 data released December 13, 2016 with further update at EASL April 2017.
Resolaris
Limb girdle muscular dystrophy (LGMD) 2B / Adult patients with facioscapulohumeral muscular dystrophy (FSHD)
Phase 1/2 interim data noted treatment was generally safe and well tolerated - December 12, 2019. Final data due mid-2020.
ATYR1923
Pulmonary sarcoidosis

Latest News

  1. aTyr Pharma Announces Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of ATYR1923 in Japan

    aTyr eligible to receive up to $175 million in total payments, including $8 million upfront, plus tiered sales royalties Kyorin to fund all ATYR1923 development and commercialization activities in Japan SAN DIEGO, Jan.

  2. aTyr Pharma Announces Third Quarter 2019 Results and Provides Corporate Update

    Interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients due in December 2019 Company to host conference call and webcast today, November 14, at 5:00pm EDT SAN DIEGO,

  3. aTyr Pharma to Present at the Stifel Healthcare Conference 2019

    SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  4. aTyr Pharma to Announce Third Quarter Results on November 14th

    SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  5. aTyr Pharma Announces Research Collaboration with Boston Children's Hospital

    SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  6. aTyr Pharma to Participate in September Conferences

    SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  7. aTyr Pharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today